Tenax Therapeutics (NASDAQ:TENX) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Tenax Therapeutics (NASDAQ:TENXFree Report) in a research note published on Friday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Separately, Roth Mkm reissued a buy rating on shares of Tenax Therapeutics in a research report on Tuesday, February 20th.

Read Our Latest Analysis on Tenax Therapeutics

Tenax Therapeutics Price Performance

TENX opened at $3.10 on Friday. The firm has a 50 day moving average price of $3.58 and a 200 day moving average price of $8.56. Tenax Therapeutics has a 1 year low of $3.03 and a 1 year high of $61.20.

Tenax Therapeutics (NASDAQ:TENXGet Free Report) last posted its earnings results on Tuesday, May 14th. The specialty pharmaceutical company reported ($3.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.72). As a group, analysts forecast that Tenax Therapeutics will post -7.96 earnings per share for the current fiscal year.

Tenax Therapeutics Company Profile

(Get Free Report)

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.

Recommended Stories

Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.